439 related articles for article (PubMed ID: 12374454)
1. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
2. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
[TBL] [Abstract][Full Text] [Related]
3. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.
Andersson BS; Kashyap A; Gian V; Wingard JR; Fernandez H; Cagnoni PJ; Jones RB; Tarantolo S; Hu WW; Blume KG; Forman SJ; Champlin RE
Biol Blood Marrow Transplant; 2002; 8(3):145-54. PubMed ID: 11939604
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.
Fernandez HF; Tran HT; Albrecht F; Lennon S; Caldera H; Goodman MS
Biol Blood Marrow Transplant; 2002; 8(9):486-92. PubMed ID: 12374453
[TBL] [Abstract][Full Text] [Related]
5. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
Andersson BS; Thall PF; Madden T; Couriel D; Wang X; Tran HT; Anderlini P; de Lima M; Gajewski J; Champlin RE
Biol Blood Marrow Transplant; 2002; 8(9):477-85. PubMed ID: 12374452
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation.
Qiao J; Fu J; Fang T; Huang Y; Mi H; Yang N; Chen C; Xu K; Zeng L
Exp Mol Pathol; 2015 Feb; 98(1):73-8. PubMed ID: 25533545
[TBL] [Abstract][Full Text] [Related]
7. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia.
Mitsuhashi K; Kako S; Shigematsu A; Atsuta Y; Doki N; Fukuda T; Kanamori H; Onizuka M; Takahashi S; Ozawa Y; Kurokawa M; Inoue Y; Nagamura-Inoue T; Morishima Y; Mizuta S; Tanaka J;
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2194-2200. PubMed ID: 27638362
[TBL] [Abstract][Full Text] [Related]
9. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.
Andersson BS; Madden T; Tran HT; Hu WW; Blume KG; Chow DS; Champlin RE; Vaughan WP
Biol Blood Marrow Transplant; 2000; 6(5A):548-54. PubMed ID: 11071260
[TBL] [Abstract][Full Text] [Related]
10. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
11. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.
Sobecks RM; Rybicki L; Yurch M; Kalaycio M; Dean R; Andresen S; Pohlman B; Duong H; Bolwell B; Copelan E
Bone Marrow Transplant; 2012 May; 47(5):633-8. PubMed ID: 21874055
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.
Nagler A; Labopin M; Berger R; Bunjes D; Campos A; Socié G; Kröger N; Goker H; Yakoub-Agha I; Shimoni A; Mohty M; Rocha V
Bone Marrow Transplant; 2014 May; 49(5):628-33. PubMed ID: 24535127
[TBL] [Abstract][Full Text] [Related]
13. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
14. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
15. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
Beelen DW; Trenschel R; Casper J; Freund M; Hilger RA; Scheulen ME; Basara N; Fauser AA; Hertenstein B; Mylius HA; Baumgart J; Pichlmeier U; Hahn JR; Holler E
Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
[TBL] [Abstract][Full Text] [Related]
16. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
Pasquini MC; Le-Rademacher J; Zhu X; Artz A; DiPersio J; Fernandez HF; Mineishi S; Kamishohara M; Mehta J; Nakamura Y; Ratanatharathorn V; Sobecks R; Burkart J; Bredeson C
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1424-1430. PubMed ID: 27154848
[TBL] [Abstract][Full Text] [Related]
17. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
Fang J; Zhang R; Wang H; Hong M; Wu Q; Nie D; You Y; Zhong Z; Li W; Hu Y; Xia L
Leuk Res; 2016 Jul; 46():61-8. PubMed ID: 27131062
[TBL] [Abstract][Full Text] [Related]
18. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
19. Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
McDonald GB; Evans AT; McCune JS; Schoch G; Ostrow JD; Gooley TA
Lancet Haematol; 2016 Nov; 3(11):e516-e525. PubMed ID: 27968820
[TBL] [Abstract][Full Text] [Related]
20. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
